Thymosin Alpha-1 vs LL-37: Immune Peptides Compared

By NorthPeptide Research Team · April 14, 2026

Two Immune Peptides, Two Different Jobs

Immunology research peptides tend to get lumped together under the label "immune support," but that category covers a vast biological territory. Thymosin Alpha-1 (Tα1) and LL-37 are both naturally occurring human peptides with well-established immunological activity — but they are studied for completely different problems, operate through distinct molecular pathways, and have separate bodies of clinical evidence behind them.

This comparison article breaks down what each peptide does, where the science is strongest, how they differ on key parameters, and which research contexts favor one over the other.

Thymosin Alpha-1: The Adaptive Immunity Specialist

Origin and Structure

Thymosin Alpha-1 is a 28-amino-acid peptide produced naturally by the thymus gland — the organ responsible for T-cell education and maturation. It was isolated from calf thymus and sequenced in 1977 by Allan Goldstein and colleagues, working from Thymosin Fraction 5, a bovine thymic extract (PMID: 265536). The synthetic form, thymalfasin, has been approved as a pharmaceutical product (Zadaxin) in more than 35 countries for treatment of chronic hepatitis B, hepatitis C (as combination therapy), and as an immune adjunct in some cancer indications. It has received FDA orphan drug designation for hepatocellular carcinoma.

Mechanism: Adaptive Immunity Orchestration

TA-1's immunological activity is concentrated in the adaptive immune system — the arm responsible for antigen-specific, targeted responses:

• T-cell maturation and differentiation — TA-1 promotes the maturation of immature T-cell precursors into functional CD3+, CD4+, and CD8+ T lymphocytes, effectively supplementing the declining output of an aging or involuted thymus gland.
• Dendritic cell activation — TA-1 drives the maturation of dendritic cells (the professional antigen-presenting cells), increasing their expression of co-stimulatory molecules (CD80, CD86) and enhancing their capacity to prime naive T-cells.
• Toll-like receptor (TLR) signaling — TA-1 matures dendritic cells through MyD88-dependent Toll-like receptor signaling, and in mice activates a TLR9/MyD88/IRF7-dependent antiviral response. This amplifies the bridge between the innate detection of pathogens and the adaptive response that clears them (PMID: 14982877, PMID: 17804687).
• Th1 shift — TA-1 polarizes the T-helper cell balance toward Th1 dominance, characterized by interferon-gamma (IFN-γ) and IL-12 production. Th1-skewed responses are the principal defense against intracellular pathogens, viruses, and tumor cells.
• NK cell enhancement — Natural killer cell cytotoxicity and proliferation are augmented, strengthening the innate surveillance system that detects virus-infected and malignant cells before adaptive responses are fully mounted.
• MHC class I upregulation — TA-1 increases MHC I expression on tumor cells and antigen-presenting cells, improving T-cell recognition of abnormal cells.
• Regulatory T-cell modulation — TA-1 also acts on regulatory T-cells, though the data are early. In vitro, incubating peripheral blood mononuclear cells from gastric cancer patients with TA-1 raised the CD4+CD25+Foxp3+ Treg fraction from 1.68% to 2.19% (PMID: 22245858). Whether that reads as a useful self-regulatory brake or as unwanted immune suppression depends on the setting, and it has not been shown to matter clinically.

Clinical Data Highlights

TA-1's evidence base is among the most extensive of any research peptide:

• The pooled evidence for TA-1 monotherapy in chronic hepatitis B comes from a meta-analysis in Alimentary Pharmacology & Therapeutics (2001) of 5 randomized controlled trials, 353 patients, comparing thymosin against placebo or usual care. The benefit is real but delayed and narrower than it is usually described: virological response was not better at the end of treatment (OR 0.56, 95% CI 0.20–1.52) or at 6 months (OR 1.67, 0.83–3.37), and reached significance only 12 months after treatment stopped (OR 2.67, 1.25–5.68). Biochemical response never differed from control at any timepoint (PMID: 11736720).
• The largest sepsis trial is ETASS — a multicenter, single-blind, randomized controlled trial in 361 severe sepsis patients, published in Critical Care. 28-day all-cause mortality was 26.0% with TA-1 versus 35.0% with conventional therapy alone, a relative risk of 0.74 (95% CI 0.54–1.02) that did not clear the conventional significance threshold on the primary analysis (P = 0.062; log-rank P = 0.049). What was significant was the immune parameter: monocyte HLA-DR recovery was greater with TA-1 at day 3 and day 7 (PMID: 23327199).
• Cancer studies — particularly in hepatocellular carcinoma and NSCLC — have reported improved immune function parameters and some progression-free survival benefits when TA-1 was added to standard therapy.
• Influenza and hepatitis B vaccine studies in elderly and immunocompromised populations have documented enhanced antibody responses with TA-1 co-administration.

LL-37: The Innate Immune Defender

Origin and Structure

LL-37 is a 37-amino-acid peptide — the sole human cathelicidin antimicrobial peptide — derived from the precursor protein hCAP18 through proteolytic cleavage by proteinase 3. Its name refers to its two N-terminal leucine residues. LL-37 is produced by neutrophils, macrophages, epithelial cells, and keratinocytes, and is found in wound fluid, sweat, saliva, breast milk, and mucosal surfaces. Its expression is upregulated by vitamin D, infection, and inflammation.

More than 2,500 PubMed-indexed publications mention LL-37, making it one of the most thoroughly studied host defense peptides in the antimicrobial peptide (AMP) literature. A small number of LL-37-based and LL-37-derived compounds have reached early-phase clinical testing.

Mechanism: Innate Immune Execution

LL-37's activities are primarily anchored in the innate immune system — the first-responder arm that acts before antigen-specific adaptive responses can be mounted:

• Membrane disruption — LL-37 adopts an amphipathic alpha-helical structure in the presence of lipid membranes. Its positively charged face interacts with negatively charged microbial membranes, inserting into and destabilizing the lipid bilayer. This produces membrane permeabilization, ion leakage, and rapid microbial death. Mammalian membranes are relatively resistant due to higher cholesterol content.
• Broad-spectrum antimicrobial activity — LL-37 has demonstrated activity against Gram-positive bacteria (including MRSA and Streptococcus species), Gram-negative bacteria (E. coli, Pseudomonas aeruginosa, Klebsiella pneumoniae), fungi (Candida albicans), and enveloped viruses (influenza, RSV, HIV).
• Biofilm disruption — One of LL-37's most studied properties is its in vitro ability to prevent biofilm formation, disrupt established biofilms, and kill bacteria within biofilm matrices. This anti-biofilm activity has been documented in vitro against P. aeruginosa, S. aureus, and S. epidermidis — pathogens that are notoriously resistant to conventional antibiotics in biofilm state. No clinical trial of LL-37 or an LL-37-derived peptide has measured biofilm eradication as an endpoint.
• LPS neutralization — LL-37 binds and neutralizes lipopolysaccharide (LPS/endotoxin), the virulence factor of Gram-negative bacteria that drives the septic cascade via TLR4 activation. This anti-endotoxin mechanism is thought to limit sepsis progression.
• Immune cell chemotaxis — LL-37 recruits neutrophils, monocytes, T-cells, and mast cells to infection sites through FPRL1 (formyl peptide receptor-like 1) activation.
• Wound healing promotion — Beyond antimicrobial defense, LL-37 promotes wound healing through keratinocyte migration, fibroblast proliferation, and angiogenesis (new blood vessel formation via FPRL1 and VEGF pathways).
• Dendritic cell maturation — LL-37 promotes DC maturation and antigen presentation, providing a bridge from innate to adaptive immunity — an overlap with TA-1's territory, though through different mechanisms.

Clinical Data Highlights

LL-37's clinical evidence is less mature than TA-1's but includes important translational data:

• OP-145 (also designated P60.4Ac), an LL-37-derived peptide, was tested as ototopical drops in adults with chronic suppurative otitis media: a 16-subject dose-finding study followed by a randomized, double-blind, placebo-controlled phase IIa trial in 34 subjects. Treatment success was 47% with the peptide versus 6% with placebo, and it was safe and well tolerated. Note the endpoint was blinded otoscopic symptom scoring — the trial did not measure biofilm eradication, which for this peptide is an in vitro finding (PMID: 32287316).
• LL-37 itself has been through two trials in hard-to-heal venous leg ulcers, and the larger one was negative. A 34-patient first-in-man study found faster healing at the two lower topical doses (PMID: 25041740), but the follow-up phase IIb trial in 148 patients found no significant healing benefit over placebo across the full study population; only a post hoc subgroup with wounds of at least 10 cm² improved (PMID: 34687253). This is the most rigorous clinical test LL-37 has faced and it did not pass it.
• Chronic wound tissue is deficient in this peptide. hCAP18/LL-37 rises sharply in acute human skin wounds and falls back as they close, while in chronic ulcers the levels are low and LL-37 immunoreactivity is absent from the ulcer-edge epithelium; blocking LL-37 with antibodies inhibits re-epithelialization in organ-cultured human skin (PMID: 12603850).
• The vitamin D–LL-37 axis is well established mechanistically: Toll-like receptor activation of human macrophages upregulates the vitamin D receptor and induces cathelicidin (PMID: 16497887). Evidence that supplementation raises circulating LL-37 in people is thinner — a randomized, placebo-controlled trial in 30 ICU patients with severe sepsis found plasma LL-37 rose a median 30% on 400,000 IU cholecalciferol against a 17% fall on placebo (P = 0.04), and its authors called for larger trials before the finding is relied on (PMID: 26086941).

Head-to-Head Comparison

Adaptive vs. Innate: Why the Distinction Matters

The adaptive and innate immune systems are not competitors — they work in sequence and in concert. Innate immunity (LL-37's domain) acts immediately, within minutes to hours, when a pathogen is detected. Adaptive immunity (TA-1's domain) takes days to weeks to mount a targeted response but produces long-lasting immunological memory.

In research terms, this means TA-1 and LL-37 are more complementary than competitive. A researcher studying chronic viral infection — where T-cell dysfunction and immune exhaustion are central problems — would reach for TA-1. A researcher studying drug-resistant bacterial wound infections — where biofilm formation and direct killing capacity are the core challenge — would reach for LL-37. A researcher investigating the overlap, such as sepsis (which involves both innate dysregulation and adaptive immune collapse), might find both relevant.

Which Peptide for Which Research Application?

Favor Thymosin Alpha-1 for:

• Chronic viral infection models (hepatitis B/C, immunosuppression states)
• Cancer immunology research (T-cell response enhancement, antigen presentation)
• Vaccine adjuvancy studies (improving antibody responses in aged or immunocompromised models)
• Sepsis immunoparalysis research (monocyte HLA-DR restoration, lymphocyte recovery)
• Age-related immune decline (thymic involution, immunosenescence models)

Favor LL-37 for:

• Antimicrobial resistance research (MRSA, MDR Gram-negatives)
• Biofilm disruption studies (chronic wound infections, device-related infections)
• Chronic wound healing models (diabetic ulcers, pressure injuries)
• Innate immune signaling studies (cathelicidin biology, vitamin D–immunity axis)
• Topical delivery and transdermal peptide research

Key PubMed References

1. Garaci E, Pica F, Rasi G, Favalli C. "Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application." Int J Immunopharmacol. 2000. Review. PMID: 11137613
2. Liu Y et al. "Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells." Clin Infect Dis. 2020. Retrospective review of 76 severe COVID-19 cases, not a randomized trial. PMID: 32442287
3. Wu J et al. "The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial." Crit Care. 2013. PMID: 23327199
4. Chan HL, Tang JL, Tam W, Sung JJ. "The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis." Aliment Pharmacol Ther. 2001. PMID: 11736720
5. Dürr UH, Sudheendra US, Ramamoorthy A. "LL-37, the only human member of the cathelicidin family of antimicrobial peptides." Biochim Biophys Acta. 2006. Review. PMID: 16716248
6. Vandamme D, Landuyt B, Luyten W, Schoofs L. "A comprehensive summary of LL-37, the factotum human cathelicidin peptide." Cell Immunol. 2012. Review. PMID: 23246832
7. Liu PT et al. "Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response." Science. 2006. PMID: 16497887
8. Mahlapuu M et al. "Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial." Wound Repair Regen. 2021. Phase IIb; primary efficacy analysis negative. PMID: 34687253

This article is for informational and research purposes only. It does not constitute medical advice. All peptides sold by NorthPeptide are intended exclusively for laboratory and research use. Not for human consumption.